Prosecution Insights
Last updated: November 04, 2026

Bioshare AB

Technology areas: Chemistry & Materials • Medical Devices & Mechanical Engineering

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready

Analysis

Bioshare AB currently has 2 pending office actions in the Medical Devices & Mechanical Engineering technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. LAU, JASON is the busiest examiner, managing 1 pending office action.

The distribution of 2 pending office actions across 2 distinct examiners indicates that the company's active cases are being handled independently. This lack of examiner overlap means that the legal team must interact with two different individuals, each with their own examination style. The presence of 2 distinct art units further suggests that the 2 pending office actions involve different technical sub-specialties. Practitioners should be prepared for two separate prosecution tracks, as the influence of LAU, JASON is limited to 1 pending office action. This decentralized structure for a small portfolio requires careful attention to ensure that arguments made to one examiner do not conflict with those made to the other. The involvement of 2 distinct examiners for the 2 pending office actions highlights the need for individualized attention to each application's unique requirements.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
1
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (50%)
Double-patenting + other1 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
50% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
50% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
LAU, JASON 1 54.1% +15.9%
CHANDLER, KAITY V 1 64.4% +22.7%

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18519022 Bubbling Fluidized Bed Reactor CHANDLER, KAITY V 27d
18728865 Continuous Char Separation Reactor LAU, JASON —

Top Art Units

Art UnitApps
3762 1
1725 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18728865 Continuous Char Separation Reactor LAU, JASON 3762 §103 Non-Final OA — Pending Jul 13, 2024
18519022 Bubbling Fluidized Bed Reactor CHANDLER, KAITY V 1725 §103DP Final Rejection 27d Pending Nov 26, 2023

Managing Bioshare AB's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Bioshare AB have?

Bioshare AB has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most Bioshare AB applications?

Jason Lau has the most, with 1 of Bioshare AB's pending office actions.

What technology area are Bioshare AB's patent applications in?

Mostly Medical Devices & Mechanical Engineering (USPTO Tech Center 3700), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month